Article Sidebar

Submitted
Nov 5, 2024
Published
Nov 5, 2024
Download
PDF
Statistic
Read Counter : 21 Download : 12

Main Article Content

Abstract

The review article provides an in-depth exploration of asthma, a chronic inflammatory disease influenced by a complex interplay of genetic and environmental factors. It traces the historical development of asthma's definition and diagnosis, from early medical descriptions to modern epidemiological studies that reveal its rising prevalence. The article discusses the pathophysiology of asthma, focusing on immune responses involving T helper type 2 (Th2) cells and cytokines, along with molecular mechanisms like IgE production and airway remodeling. Genetic factors, such as mutations in the ADAM33 and filaggrin genes, are examined for their role in asthma susceptibility and disease progression. Different asthma types—such as adult-onset, exercise-induced, and cough-induced—are reviewed, highlighting their unique triggers and diagnostic challenges. Treatment strategies, including conventional medications (inhaled corticosteroids, β2-agonists) and alternative therapies (phytochemicals), are evaluated, along with the limitations of current treatments and the need for improved therapeutic options. The article underscores the importance of personalized approaches to asthma management based on individual genetic and environmental profiles.

Keywords

Asthma inflammation treatment medicinal plant

Article Details

How to Cite
Sethuramani A, Chandrasamy M, Ajith P, Saranya S, Sasikumar A, & T. Venkata Rathina Kumar. (2024). Comprehensive Review of Asthma: Pathophysiology, Genetic Influences, and Emerging Treatment Strategies. International Journal of Research in Pharmacology & Pharmacotherapeutics, 13(4), 495-504. Retrieved from https://ijrpp.com/ijrpp/article/view/581
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. 1. Sakula A. Henry hyde salter (1823-71): A biographical sketch. Thorax 1985;40:887-8.
  2. 2. Vyas H, Krishnaswamy G. Paul ehrlich’s “Mastzellen”--from aniline dyes to DNA chip arrays: A historical review of developments in mast cell research. Methods Mol Biol 2006;315:3-11.
  3. 3. McEwen BJ. Eosinophils: A review. Vet Res Commun 1992;16:11-44.
  4. 4. 4 Mims JW. Asthma: definitions and pathophysiology. Int Forum Allergy Rhinol. 2015;5(Suppl 1):S2-S6.
  5. 5. Castillo JR, Peters SP, Busse WW. Asthma exacerbations: pathogenesis, prevention, and treatment. J Allergy Clin Immunol Pract. 2017;5:918-927.
  6. 6. Papiris S, Kotanidou A, Malagari K, Roussos C. Clinical review: severe asthma. Crit Care. 2002;6:30-44.
  7. 7. McCracken JL, Veeranki SP, Ameredes BT, Calhoun WJ. Diagnosis and management of asthma in adults: a review. JAMA. 2017;318:279-290
  8. 8. Ellwood P, Asher MI, Beasley R, Clayton TO, Stewart AW, Committee IS. The international study of asthma and allergies in childhood (ISAAC): phase three rationale and methods. Int J Tubercul Lung Dis. (2005) 9:10–6.
  9. 9. Weiland SK, Bjorksten B, Brunekreef B, Cookson WO, von Mutius E, Strachan DP, et al. Phase II of the international study of asthma and allergies in childhood (ISAAC II): rationale and methods. Eur Respirat J. (2004) 24:406–12. doi: 10.1183/09031936.04.00090303
  10. 10. Asher MI, Keil U, Anderson HR, Beasley R, Crane J, Martinez F, et al. International Study of Asthma and Allergies in Childhood (ISAAC): rationale and methods. Eur Respirat J. (1995) 8:483–91. doi: 10.1183/09031936.95.08030483
  11. 11. Variations in the prevalence of respiratory symptoms, self-reported asthma attacks, and use of asthma medication in the European Community Respiratory Health Survey (ECRHS). Eur Respir J. (1996) 9:687–95. doi: 10.1183/09031936.96.09040687
  12. 12. Asher MI, Montefort S, Bjorksten B, Lai CK, Strachan DP,Weiland SK, et al.Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. (2006) 368:733–43. doi: 10.1016/S0140-6736(06)69283-0
  13. 13. Eder W, Ege MJ, von Mutius E. The asthma epidemic. N Engl J Med. (2006) 355:2226–35. doi: 10.1056/NEJMra054308.
  14. 14. Frew AJ: Allergen immunotherapy. J Allergy Clin Immunol 2010, 125:S306-313. Kaplan AG, Balter MS, Bell AD, Kim H, McIvor RA: Diagnosis of asthma in adults. CMAJ 2009, 181:E210-E220.
  15. 15. Kovesi T, Schuh S, Spier S, Bérubé D, Carr S, Watson W, McIvor RA: Achieving control of asthma in preschoolers. CMAJ 2010, 182:E172-E183.
  16. 16. Wardlaw AJ, Brightling C, Green R, Woltmann G, Pavord I. Eosinophils in asthma and other allergic diseases. Br Med Bull. 2000;56(4):985–1003.
  17. 17. Global Initiative for Asthma (GINA): Global strategy for asthma management and prevention. 2009, Available at: http://www.ginasthma. com Accessed July 15, 2010.
  18. 18. Lemanske RF, Busse WW: Asthma: Clinical expression and molecular mechanisms. J Allergy Clin Immunol 2010, 125:S95-102.
  19. 19. Kuruvilla ME, Lee FE-H, Lee GB. Understanding asthma phenotypes, endotypes, and mechanisms of disease. Clin Rev Allergy Immunol 2019;56:219e33. https://doi.org/10.1007/ s12016-018-8712
  20. 20. Peters MC, Wenzel SE. Intersection of biology and therapeutics: type 2 targeted therapeutics for adult asthma. Lancet 2020;395:371e83. https://doi.org/10.1016/S0140- 6736(19)33005-3.
  21. 21. Gordon ED, Simpson LJ, Rios CL, Ringel L, Lachowicz- Scroggins ME, Peters MC, et al. Alternative splicing of interleukin-33 and type 2 inflammation in asthma. Proc Natl Acad Sci 2016;113:8765e70. https://doi.org/10.1073/ pnas.1601914113.
  22. 22. Peters MC, Ringel L, Dyjack N, Herrin R, Woodruff PG, Rios C, et al. A transcriptomic method to determine airway immune dysfunction in T2-high and T2-low asthma. Am J Respir Crit Care Med 2019;199:465e77. https://doi.org/10.1164/rccm.201807-1291OC.
  23. 23. Shapouri-Moghaddam A, Mohammadian S, Vazini H, Taghadosi M, Esmaeili S-A, Mardani F, et al. Macrophage plasticity, polarization, and function in health and disease. JCell Physiol 2018;233:6425e40. https://doi.org/10.1002/ jcp.26429.
  24. 24. Oksel C, Custovic A. Development of allergic sensitization and its relevance to paediatric asthma. Curr Opin Allergy Clin Immunol 2018;18:109e16. https://doi.org/10.1097/ ACI.0000000000000430.
  25. 25. Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. 26.Nature 2008;454:445e54. https://doi.org/ 10.1038/nature07204
  26. 26. Bosse´ Y, Hudson TJ. Toward a comprehensive set of asthma susceptibility genes. Annu Rev Med. 2007; 58: 171_84.
  27. 27. Vercelli D. Discovering susceptibility genes for asthma and allergy. Nat Rev Immunol. 2008; 8: 169_82.
  28. 28. Holloway JW, Arshad SH, Holgate ST. Using genetics to predict the natural history of asthma? J Allergy Clin Immunol. 2010; 126: 200_9.
  29. 29. Aierken H, Wang J, Wushouer Q, Shayhidin E, Hu X, Syed I, et al. Polymorphisms of the ADAM33 gene and chronic obstructive pulmonary disease risk: a meta-analysis. Clin Respir J. 2014; 8: 108_15.
  30. 30. Holloway JW, Arshad SH, Holgate ST. Using genetics to predict the natural history of asthma? J Allergy Clin Immunol. 2010; 126: 200_9.
  31. 31. Aierken H, Wang J, Wushouer Q, Shayhidin E, Hu X, Syed I, et al. Polymorphisms of the ADAM33 gene and chronic obstructive pulmonary disease risk: a meta-analysis. Clin Respir J. 2014; 8: 108_15.
  32. 32. Smith FJ, Irvine AD, Terron-Kwiatkowski A, Sandilands A, Campbell LE, Zhao Y, et al. Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris. Nat Genet. 2006; 38: 337_42.
  33. 33. Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006; 38: 441_6.
  34. 34. van den Oord RA, Sheikh A. Filaggrin gene defects and risk of developing allergic sensitisation and allergic disorders: systematic review and meta-analysis. BMJ. 2009; 339: 2433.
  35. 35. McClafferty H. An overview of integrative therapies in asthma treatment. Curr Allergy Asthma Rep. 2012;14:464.
  36. 36. Scichilone N, Benfante A, Morandi L, Bellini F, Papi A. Impact of extrafine formulations of inhaled corticosteroids/long-acting beta-2 agonist combinations on patient related outcomes in asthma and COPD. PatientRelat Outcome Meas. 2014;5:153–62.
  37. 37. FDA Drug Safety Communication. Drug labels now contain updated recommendations on the appropriate use of long-acting inhaled asthma medications called Long-Acting Beta-Agonists (LABAs). 2011. http://www.fda.gov/Drugs/DrugSafety/ucm251512.